Despite being amongst the most common oncogenes in human cancer, to date there are no effective clinical options for inhibiting KRAS activity. We investigated whether systemically delivered KRAS siRNAs have therapeutic potential in KRAS mutated cancer models. We identified KRAS siRNA sequences with notable potency in knocking-down KRAS expression.
INTRODUCTION
Since its discovery over 30 years ago(1, 2), the KRAS proto-oncogene has remained the single most elusive cancer target. Despite the vast heterogeneity of all malignancies, mutational activation of the RAS GTPases (HRAS, NRAS and KRAS) are present in approximately a third of all cancers (3) . While these small monomeric GTPases are part of a superfamily of more than 150 members, direct mutation of other members is rare (4) . Typically, RAS activation is catalyzed by guanine nucleotide exchange factors (GEFs) to a GTP-bound state, and subsequently hydrolyzed by GTPase-activating proteins (GAPs) to its inactive, GDP-bound state. However, KRAS missense mutations in codons 12, 13, or 61 sterically interfere with GAP hydrolysis, leading to constitutive activation and promotion of many cancer hallmarks, such as cellular proliferation, survival, cytoskeletal reorganization, and motility (5) . While valiant attempts have been made to develop pharmaceutical inhibitors of mutant KRAS-driven cancers, KRAS itself is still widely regarded as 'undruggable'.
Since the first report of RNA interference (RNAi) in 1998 (6) , there has been an explosion in efforts to utilize such a strategy for therapeutic gain (7) . Therapeutic RNAi is especially attractive because it enables silencing of cancer molecular targets that otherwise may not be inhibited using conventional approaches. While competitive ATP kinase inhibitors (e.g., imatinib) or monoclonal antibodies (e.g., trastuzumab) have revolutionized treatment of some cancers (8, 9) , the lack of such success in KRAS targeting prompted us to investigate whether RNAi has therapeutic potential for drug development. Here, we report a proof-of-concept study in lung and colon cancer preclinical models that demonstrates the efficacy of KRAS silencing using nanoparticle-mediated siRNA delivery. Additionally, we demonstrate in several models that KRAS silencing in vivo can potently inhibit development of metastatic disease, the cause of death in approximately 90% of cancer patients (10) . mixture of HBSS and BD Matrigel (BD Biosciences)] as previously described (12) . For the intrapulmonary injections, mice were anesthetized with ketamine + xylazine and placed in the right lateral decubitus position. Following skin cleaning with an alcohol swab, an incision parallel to the rib cage between ribs 10-11 was made to visualize the lung through the thorax. A 1 mL tuberculin syringe with a 30-g needle was used to inject the cell suspension directly into the lung parenchyma at the left lateral dorsal axillary line. After injection the incision was closed using surgery clips and the mice were turned on the left lateral decubitus until fully recovered.
MATERIALS AND METHODS
For both colon cancer models, 2.5x10 5 HCP1 cells per mouse 100 µL HBSS were either injected subcutaneously or intra-splenic (experimental liver metastases model). In the liver metastases model, mice were anesthetized under isofluorane for splenic isolation and cell line injection (day 1), as well as the following day after injection (day 2) in order to perform splenectomy (11) . Treatment continued until mice in any group became moribund (approximately 3 weeks).
For the A549 xenograft time-kinetic experiment used to assess for KRAS knock-down following siRNA delivery, 2.5x10 6 A549 parental cells were injected subcutaneously into athymic nude mice. Mice were randomly assigned to receive either NC siRNA or the combination of KRAS siRNAs Seq #2 and #3 (150 µg siRNA/kg/mouse). After 4 weeks of cell line injection, For all therapeutic experiments, mice were randomly divided and assigned to their respective treatment groups (n=10 mice/group). A dose of 150 µg siRNA/kg/mouse was packaged within DOPC nanoliposomes and delivered intra-peritoneally at twice weekly intervals as previously described (13) . In all experiments, once mice in any group became moribund they were all sacrificed, by use of an enhanced chemiluminescence detection kit (Pierce). To confirm equal sample loading, the blots were probed with an antibody specific for Vinculin. Densitometry was calculated using ImageJ software.
Quantitative real-time PCR. For mRNA quantification, total RNA was isolated by using a Qiagen RNeasy kit. Using 500 ng of RNA, cDNA was synthesized by using a Verso cDNA kit peroxidase activity for 10 minutes. Protein blocking of non-specific epitopes was done using either 5% normal horse serum, 1% normal goat serum or 2.8% fish gelatin in either PBS or TBS-T for 20 minutes. Slides were incubated with primary antibody for Ki-67 (rabbit anti-mouse, 1:200, Abcam ab15580) or cleaved caspase-3 (BioCare Medical, 1:100) overnight at 4 ºC.
Terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) staining was performed using Promega Kit (Promega, Medison, WI), and CD31 staining to assess microvessel density were performed as previously described (12, 14) . For immunohistochemistry, after washing with PBS, the appropriate amount of horseradish peroxidase-conjugated secondary antibody was added and visualized with 3,3'-diaminobenzidine chromogen and counterstained with Gill's hematoloxylin #3. Light field images were obtained using a Nikon Microphot-FXA microscope and Leica DFC320 digital camera.
Proliferation and apoptotic indices were determined using 6-10 representative fields at 200x magnification for each tumor, while microvessel density was determined at 100x magnification (5 tumors per group). Ki-67 and cleaved caspase-3 positive cells per high-powered field were enumerated using Cell Profiler 2.0 software, while TUNEL positive cells per high-powered field were enumerated manually (15) . Quantification was performed in a blinded fashion.
Statistical Analysis. For animal experiments, 10 mice were assigned per treatment group. This sample size provided 80% power to detect a 50% reduction in tumor mass with 95% confidence. Mouse and tumor weights and the number of tumor nodules for each group were compared using Student t test (for comparisons of two groups) and analysis of variance (for multiple group comparisons). For values that were not normally distributed (as determined by the Kolmogrov-Smirnov test), the Mann-Whitney rank sum test was used. A P value < 0.05 was deemed statistically significant. All statistical tests were two-sided and were performed using GraphPad Prism 6.0. 
RESULTS

Selection of potent KRAS siRNA sequences
To test the efficacy of KRAS silencing in vivo, we first searched for siRNA sequences that potently inhibit KRAS expression regardless of the specific missense mutation at codons 12, 13 or 61. Low concentrations (20 nM) of two siRNA sequences (Seq #2 and Seq #3) within the coding sequence were found to inhibit KRAS mRNA expression in mutant (A549 lung adenocarcinoma, KRAS G12S ) and wild-type (RMUG-S ovarian carcinoma) cell lines (Fig. 1A+B ).
Western blots further confirmed greater than 90% knock-down of KRAS protein in mutant (A549) and wild-type (H1299, RMUG-S) cancer cell lines (Fig. 1C) . Compared with negative control (NC) siRNA, a single transfection of Seq #2 or Seq #3 siRNAs significantly inhibited cell viability in the A549 cell line, but not in the wild-type cells (Fig. 1D) , suggesting attenuated growth is not due to off-target effects of the siRNA sequences and is consistent with A549
having a KRAS oncogene "addiction" (16) . Furthermore, the combination of Seq #2 and Seq #3
at low concentrations (10 nM or 20 nM) led to substantial reductions in cell viability (Fig. 1D ). As compared with H1299, KRAS siRNA sequences #2 and #3 in A549 led to marked reductions in pERK and pMEK, molecules involved in the downstream signaling of the MAPK pathway (Fig.   1E ).
Therapeutic Efficacy of KRAS siRNAs in a Lung Cancer Model
Using our well-characterized 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC) nanoliposomes ( Supplementary Fig. 1 ) (13), we have recently demonstrated highly effective systemic delivery of oligonucleotides in orthotopic lung cancer models (12) . Through exploitation of the enhanced-permeability and retention (EPR) effect (7), we also demonstrated the ability to systemically deliver siRNAs to metastatic lesions (12) . Thus, for all in vivo experiments, we assessed therapeutic efficacy of KRAS targeting with DOPC-mediated siRNA delivery. In addition to primary tumors, this model demonstrated the ability to form mediastinal lymph node and chest wall metastases (Fig. 2B ).
One week following orthotopic injection of 7.5x10 5 A549-Luc cells, mice were randomly assigned to the following treatment groups (n=10 mice/group): (1) NC siRNA-DOPC, (2) KRAS siRNA-DOPC, (3) NC siRNA-DOPC+CDDP and (4) KRAS siRNA-DOPC+CDDP. For the KRAS siRNA treatment groups, Seq #2 and Seq #3 were combined. For the CDDP treatment groups, 160 μg of CDDP was given intra-peritoneally once weekly. One week after cell line injection, twice-weekly treatment commenced and weekly imaging was performed (Fig. 2C) . Following four weeks of systemic therapy, compared to control siRNA treatment, mice in the KRAS siRNA treatment group had an 81% reduction in luminescence (P<0.01), while the addition of CDDP did not lead to significant reductions in the NC siRNA+CDDP or KRAS siRNA+CDDP groups (Fig. 2D+E) . Longitudinal assessments of luciferase activity demonstrated significant growth inhibition from KRAS siRNA treatment (Fig. 2F) , and rapid disease progression during the last week of treatment was significantly attenuated as compared with NC siRNA (Fig. 2G) . Following four weeks of treatment, all mice were sacrificed and an extensive necropsy of gross tumor burden was quantified. As compared with control siRNA, significant reductions in primary tumor (Fig. 2H+I, Supplementary Fig. 2 ). The number of distant metastases was only significantly decreased in the KRAS siRNA+CDDP group (Fig. 2J) .
Intriguingly, only the KRAS siRNA treatment groups had significantly less frequent mediastinal metastases, while NC siRNA+CDDP did not (Fig. 2K) . Taken together, systemically delivered KRAS siRNAs demonstrated significant therapeutic activity on the primary tumor as well as control of metastatic spread; while the addition of cytotoxic chemotherapy was not additive.
To further assess the biological effects of systemic KRAS siRNA treatment, we stained the tumor samples for proliferation, apoptosis and angiogenesis markers. Compared with control siRNA, significant increases in caspase-3 activity and TUNEL staining were observed in all treatment groups, with the greatest effects seen in the KRAS siRNA+CDDP group (Fig.   3A+B ). Compared with control siRNA, significant reductions in Ki-67 indices were seen in all treatment groups (KRAS siRNA: 34%, NC siRNA+CDDP: 52%, KRAS siRNA+CDDP: 36%; all P<0.0001) (Fig. 3C) . Also, compared with control siRNA, all treatment groups had significant reductions in microvessel density (KRAS siRNA: 61%, NC siRNA+CDDP: 55%, KRAS siRNA+CDDP: 76%; all P<0.001) (Fig. 3D) . Compared with NC siRNA+CDDP, KRAS siRNA+CDDP had a 45% reduction in microvessel density (P<0.05, Fig. 3D ). These data indicate that in vivo silencing of KRAS in tumors leads to induction of apoptosis and inhibition of proliferation and angiogenesis. Although the combination of KRAS siRNA with cisplatin had additive biological effects on the tumors (Fig. 3A-D . Mice were randomly assigned to the following treatment groups (n=10 mice/group): (1) NC siRNA-DOPC or (2) KRAS siRNA-DOPC. Twice weekly treatments were given and tumor volumetric assessments were made with calipers every three days. As soon as one week after treatment, significant reduction in tumor growth was noted in the KRAS siRNA-DOPC group, and following two weeks of treatment, tumors were 68.6%
smaller (P=0.033) than the NC siRNA group (Fig. 4B ).
Because the predominant site of distant metastasis in patients with colon cancer is the liver, we assessed whether KRAS siRNA would be effective in an experimental metastasis model. Splenectomy was performed one day following intra-splenic injection of 2. Using mutant KRAS models of lung and colon cancer, we demonstrate the therapeutic potential of systemically delivered RNAi as a novel treatment modality. While therapeutic effects were seen through decreased downstream signaling and inhibition of proliferation, we also observed significant decreases in the frequency and burden of distant metastases. KRAS siRNA delivery as a therapeutic approach has many characteristics that make it desirable for further drug development. First, so far the first-in-human clinical trials using nanoparticlemediated siRNA delivery have been safe, well tolerated and in some cases have led to 
complete pathologic responses in metastatic disease (24, 25) . Second, while in this proof-ofconcept study siRNA sequences which targeted all forms of mutant KRAS (and wild-type) were used, siRNA sequences that preferentially target only the mutant allele could be developed, thus theoretically avoiding toxicity from targeting the wild-type protein in normal tissues. Lastly, while other current approaches rely upon blocking the effects of mutant KRAS, whose downstream mediators consist of a highly complex circuitry, use of RNAi aims at eliminating the functional capstone, KRAS itself. While therapeutic RNAi has important challenges of its own, such as developing targeted platforms that are biocompatible and potently inhibit target expression, the field is rapidly moving forward and turning this approach into a reality(7). Greatest cross-sectional dimension of the primary tumor (in mm), (i) total aggregate mass of metastatic burden (in grams), and (j) total number of metastatic lesions for each treatment group. For all experiments, each mouse received 150 μg siRNA/kg/mouse dissolved in 200 μL of PBS by the intra-peritoneal route. For the therapeutic experiment, twice weekly siRNA injections were given. Cisplatin (CDDP) was given once weekly by intra-peritoneal injection at a dose of 160 μg/mouse. N=10 mice/group, all measurements demonstrate mean ± SEM, pvalues calculated using student's t-test. (k) Frequency of mediastinal metastases by treatment group. P-value determined using chi-squared test.
* P < 0.05, ** P < 0.01, *** P < 0.001 
